On June 2, 2020 Perrigo Company plc (NYSE; TASE: PRGO) reported that President and CEO Murray S. Kessler will present further details on the Company’s consumer growth strategy along with a general update on the business at the 20th Annual Oppenheimer Consumer Growth and E-Commerce Virtual Conference at 2:00 PM EDT on Wednesday, June 17, 2020 (Press release, Perrigo Company, JUN 2, 2020, View Source [SID1234560757]). Interested parties can access the presentation webcast at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 2, 2020 MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) reported that it will present at the following virtual conferences (Press release, MorphoSys, JUN 2, 2020, View Source [SID1234560756]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Healthcare Conference
Date: June 3, 2020, 9:30am EDT (3:30pm CEST, 2:30pm BST)
Presenter: Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys,
Dr. Julia Neugebauer, Director Corporate Communications & IR

Goldman Sachs 41st Annual Global Healthcare Conference
Date: June 10, 2020, 8:50am EDT (2:50pm CEST, 1:50pm BST)
Presenter: Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys,
Dr. Julia Neugebauer, Director Corporate Communications & IR

J.P. Morgan European Healthcare Conference
Date: June 18, 2020
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys,
Dr. Julia Neugebauer, Director Corporate Communications & IR

JMP Hematology and Oncology Forum
Date: June 18, 2020
Presenter: Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys,
Dr. Julia Neugebauer, Director Corporate Communications & IR

PDF versions of the presentations will be provided at www.morphosys.com. Links to available webcasts will be filed under www.morphosys.com/conference-calls.

On June 2, 2020 Theragnostics reported our collaboration with the ‘Next generation molecular imaging and therapy with radionuclide’ (MITHRAS) programme currently launching in the UK (Press release, Theragnostics, JUN 2, 2020, View Source;utm_medium=rss&utm_campaign=theragnostics-collaborate-on-6-million-mithras-research-programme [SID1234560755]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MITHRAS is being led by Theragnostics Advisory Board member Professor Phil Blower as part of a team of 15 co-investigators including 12 from King’s College London, two from Imperial College London and one from Southampton University. The research team will also comprise post-doctoral assistants and aligned PhD students, whose work will be to design, validate and translate novel radionuclide imaging agents and radiotherapeutics.

Theragnostics involvement builds on a long term relationship with King’s College London School of Biomedical Engineering and Imaging Sciences which for over a decade, has been assembling an environment and team fit for the task of delivering this multidisciplinary programme to develop fast, efficient chemistry for novel PET imaging agents. The Imaging Chemistry and Biology Department within the School of Biomedical Engineering & Imaging Sciences has ten academic molecular imaging chemists and biologists, alongside physicists and clinicians, plus key external experts feeding in additional novel chemistry and image analysis. The programme has been awarded £6 million and will run over 5 years, with clinical translation in a range of oncology indicaions as the guiding principle."

On June 2, 2020 Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported that the Biologics License Application ("BLA") for Danyelza (naxitamab) for the treatment of patients with relapsed/refractory high-risk neuroblastoma has been accepted for priority review by the U.S. Food and Drug Administration ("FDA") (Press release, Y-mAbs Therapeutics, JUN 2, 2020, View Source [SID1234560753]). The FDA set an action date of November 30, 2020, under the Prescription Drug User Fee Act ("PDUFA"). The Agency also indicated in the BLA filing communication letter that it is not currently planning to hold an advisory committee meeting to discuss the application.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We believe that the FDA’s acceptance of our BLA for priority review of our first leading antibody compound, Danyelza (naxitamab), is a significant achievement for Y-mAbs and a crucial step forward as we anticipate that Danyelza, if approved, can address a significant unmet medical need for children with relapsed/refractory high-risk neuroblastoma," stated Thomas Gad, Founder, Chairman, President and Head of Business Development and Strategy.

Dr. Claus Moller, Chief Executive Officer, continued, "We look forward to working with the Agency to bring Danyelza to appropriate patients. We are excited to move forward and plan for a seamless commercial launch of Danyelza (naxitamab), if approved."

Researchers at Memorial Sloan Kettering Cancer Center ("MSK") developed naxitamab, which is exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests in the product.

On June 2, 2020 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, reported that recruiting has begun and the first patient has been enrolled in the Emory University Phase 1 clinical trial of WP1066 for the treatment of brain tumors in children (Press release, Moleculin, JUN 2, 2020, View Source [SID1234560752]). The study is being conducted at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. (PRNewsfoto/Moleculin Biotech, Inc.)

WP1066 is the lead molecule in Moleculin’s portfolio of immune stimulators and modulators of transcription. WP1066 has been shown in animal models to both stimulate a natural immune response, while also inhibiting the activated form of STAT3 (p-STAT3), a gene transcription factor that is considered a master regulator of tumor-related activity.

"p-STAT3 has long been considered an ‘undruggable’ target," commented Walter Klemp, Chairman and CEO of Moleculin. "We’ve shown activity in patients with WP1220, one of the other molecules in this portfolio. This trial represents another opportunity to show that p-STAT3 is a viable target. We are honored to be a part of this effort to cure childhood brain tumors."